Evidence map›Paper›PMID 32028732›Full record

ReviewPharmaceutics2020

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials-Process Perspective.

Mohammad A Azad, Deborah Olawuni, Georgia Kimbell, Abu Zayed Md Badruddoza, Md Shahadat Hossain, Tasnim Sultana

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Application of PLCL as a biodegradable polymer in biomedical engineering.Journal of materials science. Materials in medicine · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Structured engineering of self-emulsifying drug delivery systems (SEDDS)International journal of pharmaceutics: X · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Plants (Basel, Switzerland) · 2025
    Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammad A AzadDepartment of Chemical, Biological and Bioengineering, North Carolina A&T State University, Greensboro, NC 27411, USA.
Deborah OlawuniDepartment of Chemical, Biological and Bioengineering, North Carolina A&T State University, Greensboro, NC 27411, USA.
Georgia KimbellDepartment of Chemical, Biological and Bioengineering, North Carolina A&T State University, Greensboro, NC 27411, USA.
Abu Zayed Md BadruddozaDepartment of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA.
Md Shahadat HossainDepartment of Engineering Technology, Queensborough Community College, City University of New York (CUNY), Bayside, NY 11364, USA.
Tasnim SultanaDepartment of Public Health, School of Arts and Sciences, Massachusetts College of Pharmacy and Health Sciences (MCPHS), Boston, MA 02115, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three dimensional (3D) printing as an advanced manufacturing technology is progressing to be established in the pharmaceutical industry to overcome the traditional manufacturing regime of 'one size fits for all'. Using 3D printing, it is possible to design and develop complex dosage forms that can be suitable for tuning drug release. Polymers are the key materials that are necessary for 3D printing. Among all 3D printing processes, extrusion-based (both fused deposition modeling (FDM) and pressure-assisted microsyringe (PAM)) 3D printing is well researched for pharmaceutical manufacturing. It is important to understand which polymers are suitable for extrusion-based 3D printing of pharmaceuticals and how their properties, as well as the behavior of polymer-active pharmaceutical ingredient (API) combinations, impact the printing process. Especially, understanding the rheology of the polymer and API-polymer mixtures is necessary for successful 3D printing of dosage forms or printed structures. This review has summarized a holistic materials-process perspective for polymers on extrusion-based 3D printing. The main focus herein will be both FDM and PAM 3D printing processes. It elaborates the discussion on the comparison of 3D printing with the traditional direct compression process, the necessity of rheology, and the characterization techniques required for the printed structure, drug, and excipients. The current technological challenges, regulatory aspects, and the direction toward which the technology is moving, especially for personalized pharmaceuticals and multi-drug printing, are also briefly discussed.

Indexed as

extrusion-based 3D printingfused deposition modeling (FDM)materialspharmaceuticalspolymerspressure-assisted microsyringe (PAM)process

Identifiers

PMID32028732
PMCPMC7076526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.